CLAVBIO 625 Tablet IP – Amoxycillin 500 mg & Potassium Clavulanate 125 mg Antibiotic | amoxycillin clavulanate 625 mg tablet, CLAVBIO 625 Tablet IP, amoxycillin 500 mg clavulanate 125 mg tablet, antibiotic tablet 625 mg, broad spectrum antibiotic tablet, respiratory infection antibiotic, UTI antibiotic tablet, ENT infection medicine

CLAVBIO 625 Tablet IP is a fixed-dose combination of Amoxycillin 500 mg and Potassium Clavulanate 125 mg, offering a total strength of 625 mg. Amoxycillin acts by inhibiting bacterial cell wall synthesis, while clavulanate protects the antibiotic from degradation by beta-lactamase enzymes produced by resistant bacteria.

CLAVBIO 625 Tablet IP is widely prescribed for respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, and dental infections. The 625 mg formulation ensures enhanced antibacterial coverage, improved treatment outcomes, and dependable infection control in moderate to severe bacterial conditions.

Key Benefits:

✅ Contains Amoxycillin 500 mg + Potassium Clavulanate 125 mg (625 mg strength)
✅ Broad-spectrum antibacterial coverage
✅ Effective against beta-lactamase producing organisms
✅ Useful in respiratory, ENT, UTI & skin infections
✅ Ensures reliable bacterial eradication
✅ Well-tolerated oral antibiotic under medical supervision

Key Ingredients (Per Tablet):

• Amoxycillin IP – 500 mg
  Penicillin-class antibiotic that inhibits bacterial cell wall synthesis
• Potassium Clavulanate IP – 125 mg
  Beta-lactamase inhibitor that enhances antibacterial efficacy

Why Choose CLAVBIO 625 Tablet IP?

CLAVBIO 625 Tablet IP delivers the globally accepted 625 mg antibiotic combination with proven effectiveness against resistant bacterial infections. Manufactured under stringent quality standards of Riva Kenko Pharma, CLAVBIO 625 Tablet IP ensures consistent potency, safety, and dependable clinical outcomes—making it a reliable choice for everyday antibacterial therapy.